In an effort to accelerate the identification of susceptibility genes in diabetic nephropathy, the first genome-wide fluorescencebased DNA microsatellite (n ‫؍‬ 6000) association screen was performed, using pools of genomic DNA derived from Irish patients with (cases; n ‫؍‬ 200) and without (controls; n ‫؍‬ 200) type 1 diabetic nephropathy. Allele image profiles were generated for 5353 (89.2%) microsatellite markers for both case and control pools. Allele counts (estimated from allele image profiles) were compared in case versus control groups, and empirical P values were generated. Markers then were ranked on the basis of their empirical P values (lowest to highest). Repeat PCR amplification and electrophoresis of pooled samples were performed systematically on ranked markers until the 50 most associated markers with consistent results were identified. DNA samples that composed the pools then were genotyped individually for these markers. Two markers on chromosome 10, D10S558 (P corrected ‫؍‬ 0.005) and D10S1435 (P corrected ‫؍‬ 0.016), revealed statistically significant associations with diabetic nephropathy. An additional four markers (D6S281, D4S2937, D2S291, and D17S515) also are worthy of further investigation. Relevant functional candidate genes have been identified in the vicinity of these markers, demonstrating the feasibility of low-resolution genome-wide microsatellite association screening to identify possible candidate genes for diabetic nephropathy.
D
iabetic nephropathy (DN) is an extremely serious clinical complication of diabetes in which patients exhibit persistent proteinuria, hypertension, declining renal function, and an increased premature mortality largely as a result of cardiovascular disease. The pathophysiology of DN involves glomerular capillary hypertension, glomerular hyperfiltration, mesangial matrix expansion, and glomerulosclerosis (1) (2) (3) . In Western populations, DN has emerged as the leading cause of ESRD (4,5), resulting in patients' requiring dialysis and transplantation.
The risk for developing nephropathy in patients with diabetes becomes greater with increasing duration of diabetes and poor regulation of blood glucose and BP. Studies have shown, however, that irrespective of good glycemic control, some patients with diabetes still develop nephropathy (6, 7) . In addition, although administration of antihypertensive therapy to microalbuminuric patients may retard progression toward ESRD (8, 9) , irreversible structural changes in the kidney have already occurred by the time microalbuminuria is identified. Disease prevention therefore is an important goal.
Evidence from epidemiologic and family-based studies strongly suggest a role for both susceptibility and protective genes in the development of DN in type 1 diabetes. This is illustrated by the observation that the disease generally develops within 20 yr after diagnosis of type 1 diabetes, whereas the risk for developing nephropathy decreases in patients who have diabetes without nephropathy after 20 yr of duration of diabetes (10) . Also, there is strong concordance for nephropathy status among siblings with diabetes (11, 12) , and there is evidence to support the involvement of genes with major and minor effects in the pathogenesis of this disease (12, 13) .
Identification of validated genetic markers for high and low risk for nephropathy will facilitate prediction of nephropathy in patients with diabetes; this information also could lead to the development of pharmacogenetic treatments to prevent this disease. Genome-wide linkage analysis, however, has been complicated largely by difficulties in obtaining sufficient numbers of sibling pairs who have diabetes and are concordant or discordant for nephropathy. Consequently, case-control association studies, using a candidate gene approach, have become the method of choice for identifying causal gene variants that contribute to DN. A number of such studies have been per-formed, but no consistent positive associations have been identified (14 -18) . Conflicting findings may be due to several factors, including genetic heterogeneity, inadequate sample sizes, and use of inappropriate selection criteria for patients (19) .
In an attempt to identify chromosomal regions that harbor possible candidate genes for DN, we performed a low-resolution genome-wide microsatellite [i.e., anonymous nucleotide repeat units, e.g., (CA) n ] association screen, using the same method and markers used in the Genetic Analysis of Multiple sclerosis in EuropeanS (GAMES) collaborative project (20 -23; http://www-gene.cimr.cam.ac.uk/MSgenetics/GAMES). Separate pools of DNA, derived from Irish patients with type 1 diabetes and with (cases) and without (controls) nephropathy, were screened for association using 6000 fluorescently labeled microsatellite markers (the GAMES marker set). A comparison of allele image profiles (AIP; a series of peaks of varying heights reflecting the allele frequency distribution within each analyzed DNA pool) from cases and controls permitted ranking of markers according to empirical P values; individual genotyping then was performed on the 50 most associated markers. In this report, we describe the major findings of this genome-wide association screen and demonstrate the feasibility of this approach for identifying possible candidate genes in DN.
Materials and Methods

Patient Groups and Selection Criteria
Patients were recruited from Northern Ireland (n ϭ 105 cases; n ϭ 105 controls) and the Republic of Ireland (n ϭ 95 cases, n ϭ 95 controls). Parents and grandparents of patients were born in Ireland. All patients were white and had type 1 diabetes, defined as diabetes that was diagnosed before the age of 31 yr and required insulin from diagnosis. Cases with nephropathy were defined by development of persistent proteinuria (Ͼ0.5 g protein/24 h) at least 10 yr after diagnosis of diabetes, hypertension (BP Ͼ135/85 mmHg and/or treatment with antihypertensive agents), and presence of diabetic retinopathy. In contrast, controls were patients who had diabetes duration of at least 15 yr and urinary albumin in the normal range and were not receiving antihypertensive treatment. Patients with microalbuminuria were excluded from both groups. Ethical approval was obtained from the appropriate research ethics committees, and written informed consent was obtained from patients before this study was conducted.
Construction and Assessment of DNA Pools
Genomic DNA samples from cases and controls were quantified using the Picogreen method (Molecular Probes, Eugene, OR) and normalized to 10 ng/l in 10 mM Tris/0.1 mM EDTA (pH 7.6). Equal volumes (200 l) of individual DNA samples (10 ng/l) from cases and controls were combined to generate the DNA pools. Before use in the genome-wide screen, the pools were validated by comparing estimated allele frequencies that were generated from pools (five replicate AIP in each case) with allele frequencies obtained by individual genotyping of samples that composed the pools, for two randomly selected microsatellite markers, D19S49 (dinucleotide) and D7S1821 (tetranucleotide), as follows. PCR reactions (15 l in total) that contained 25 ng DNA, 5 pmol of each primer (forward primer for both markers was labeled with FAM), and 9 l of True Allele PCR Premix (Applied Biosystems, Warrington, UK) were set up. All PCR reactions were performed using an MJ Tetrad thermal cycler using the following cycling conditions; 95°C for 12 min, 10 cycles at 94°C for 15 s, 55°C for 15 s, and 72°C for 30 s followed by 20 cycles of 89°C for 15 s, 55°C for 15 s, 72°C for 30 s, and finally 72°C for 20 min. Each PCR product was diluted 10-fold in ddH 2 O; 1 l of diluted PCR product then was combined with 12 l of ROX/HiDi (prepared by combining 0.3 l of GS-400HD [ROX] and 11.7 l of HiDi formamide, both supplied by Applied Biosystems), and the mixture was subjected to capillary electrophoresis on a 3100 genetic analyser (Applied Biosystems). The raw data were exported to ABI Genescan software to confirm size labeling. Files then were imported into ABI Genotyper software, where alleles were identified appropriately.
Genome-Wide Microsatellite Genotyping
The 6000 microsatellite markers that were used in the screening phase consist of 811 that make up the Applied Biosystems high-density linkage mapping set (LMS-HD5) together with an additional 5189 identified from the Co-operative for Human Linkage Centre database (http://gai.nci.nih.gov/CHLC), the Genethon database (http://www. genethon.fr), and the Genome database (http://www.gdb.org). The total number of markers from each chromosome was chosen to reflect the number of genes that map to that chromosome (according to the National Center for Biotechnology Information web site in December 1999, http://www.ncbi.nlm.nih.gov). The density of markers therefore is biased toward gene-rich and against gene-poor chromosomes. However, markers were not selected to be necessarily intragenic. Within each chromosome, markers were selected so as to make the distribution of markers as uniform as possible according to their location scores on the genetic location database (http://cedar.genetics.soton.ac.uk/ public_html). The 6000 microsatellite markers that were used in this study resulted in an average intermarker spacing of 0.6 cM (or 0.5 Mb; Appendix 1); gender-averaged cM measurements were derived from the Marshfield Master Map (http://www.ncbi.nlm.nih.gov/mapview). There are 329 gaps Ͼ2 cM in gene-poor regions, 11 of which are Ͼ10 cM. These gaps correspond mainly to pericentromeric regions, particularly on acrocentric chromosomes, and sections of the genome that generally contain very few genes. In total, 4723 (79%) of the markers are dinucleotides, 1019 (17%) are tetranucleotides, and 258 (4%) are trinucleotides. The estimated average heterozygosity (according to data in the originating databases) of the 6000 markers is 70%. Details of the markers, including primer sequences, are available on the GAMES web site (http://www-gene.cimr.cam.ac.uk/MSgenetics/GAMES).
Aliquots of DNA (2.5 l; 25 ng) from each pool were PCR amplified by individual primer pairs that flanked the 6000 microsatellite markers as described above for pool assessment. Amplification products were subjected to capillary electrophoresis on a 3700 genetic analyser (Applied Biosystems), either as a uniplex or a triplex essentially as described above. For PCR products with AIP peak heights above 10,000 (i.e., saturated), the products were diluted and run again. To minimize electrophoretic artifacts, we performed repeat electrophoresis on all PCR products; when contradictory results were observed, PCR products were run on a third occasion to assist in resolving ambiguities. Repeat PCR amplification and electrophoresis were performed systematically on ranked markers with the smallest empirical P values as described in the Statistical Analyses section to facilitate the identification of the 50 most associated markers.
Statistical Analyses
Clinical characteristics of the patients were compared by the independent samples t test. The electrophoretic output for a given microsatellite marker using pooled DNA comprises a series of peaks, an AIP (Figure 1) , where the height of each peak reflects the frequency of the corresponding microsatellite allele. Allele counts were estimated by normalizing the observed peak heights according to the number of alleles in the respective pool. Allele counts from cases and controls then were compared using a 2 test. Because pooling introduces additional sources of variance above and beyond the expected sampling variance, exact P values cannot be determined for these statistics. We therefore used the observed distribution of results to calculate empirical P values for each marker and therefore enable their ranking (23), i.e., markers that were ranked according to lowest empirical P value showed the greatest difference between case and control AIP. To refine this ranking and reduce the effects of the additional sources of error introduced by pooling, we generated replicate AIP from both the case and control pools for each of the 63 most highly ranked markers; the total data then were reanalyzed, and the markers were reranked. Individual genotyping then was performed in the 50 most highly ranked markers to distinguish definitively those that showed genuine allele frequency differences from those that ranked highly as a result of poolinginduced variance. Results from the individual typing were tested for significance using a 2 test after amalgamation of rare alleles. When any cell in the contingency table had an expected value Ͻ5, the associated allele was pooled with the next rarest allele and this process was repeated until no cell had an expected value Ͻ5. This analysis was performed using the T2 statistic in the CLUMP program (24) . P values for individual genotyping were corrected for the total number of comparisons made in the initial analysis by DNA pooling (5353). Markers that attained significance were examined using the Clump T4 statistic; the alleles were pooled into two groups in such a way as to maximize the 2 test statistic. This pooling enabled odds ratios (OR) and 95% confidence intervals (CI) to be obtained. Table 1 lists the clinical characteristics of the case and control groups. There were a total of 84 and 124 women in the case and control groups, respectively. The age at diagnosis of diabetes was not significantly different between the groups. The mean duration of diabetes was at least 25 yr for both groups. As expected, the average BP was higher in cases versus controls, despite the use of antihypertensive drug treatment by patients with DN.
Results
Clinical Characteristics of Patients
Assessment of DNA Pools and Genome-Wide Screen
Excellent concordance was found between allele frequencies that were determined by pooling versus individual genotyping methods for D19S49 and D7S1821, in both case and control pools (data not shown). Interpretable AIP were generated for both case and control pools in 5353 (89.2%) markers. A total of 647 markers were excluded because of PCR failures in case and/or control pools or difficulties in data interpretation (e.g., weak or diffuse peaks in AIP). Markers were ranked according to empirical P value (lowest to highest). To refine the marker ranking, we systematically performed repeat PCR amplification and electrophoresis of pooled samples on the 63 most highly ranked markers until 50 markers that showed consistent results were identified. Empirical P values that were obtained for these markers were not corrected. These markers then were genotyped individually in the same samples that composed the pools (Appendix 2). Of note, two markers on chromosome 10 (D10S558 and D10S1435) revealed significant differences in allele distribution between groups after correction by the stringent Bonferroni method ( Table 2 ). The allele distributions for these two markers are presented in Table 3 and indicate that larger D10S558 alleles were associated with increased risk for nephropathy (OR 2.50; 95% CI 1.83 to 3.41), whereas the D10S1435 272 allele was associated with decreased risk (OR 0.44; 95% CI 0.32 to 0.61). Furthermore, four additional markers (D2S291, D4S2937, D6S281, and D17S515) gave small uncorrected P values, and although they failed to achieve statistical significance after Bonferroni correction, they warrant further consideration ( Table 2) .
Discussion
Genetic association studies that have used a candidate gene approach have been unsuccessful to date in identifying single-nucleotide polymorphisms (SNP) that show a consistent association with DN in type 1 diabetes. In addition, high-resolution whole-genome SNP screening in DN currently is not feasible, partly because of the extremely high total cost of SNP genotyping and uncertainty as to the composition of an appropriate panel of SNP for a comprehensive scan. However, with recent advances in novel, low-cost, highthroughput genotyping technologies (25, 26) and improvements in statistical methods for data analysis (27) , as well as projects such as the International HapMap (28), such screening certainly will be feasible in the future. It is interesting that a recent Japanese study assessed Ͼ80,000 SNP for association with DN in type 2 diabetes and a significant SNP association was reported between the engulfment and cell motility (ELMO 1) gene and DN (29) .
In this report, we applied a highly efficient but low-resolution approach for whole-genome association screening in DN that uses 6000 microsatellite markers and a DNA pooling strategy; this strategy originally was used in the GAMES collaborative project (20 -23) . Importantly, the GAMES project succeeded in identifying the well-established association of multiple sclerosis with the MHC region, confirming that the approach is able to identify microsatellites in linkage disequilibrium with genuine but modest susceptibility factors.
Strict phenotyping criteria were used in the selection of cases c Values are the average of three most recent measurements prior to recruitment. and controls in our study to reduce the possibility of false outcomes related to phenotype misclassification. In addition, all participants were white and of Irish descent, therefore reducing potential problems associated with population stratification. We identified the 50 most associated markers that showed consistent results on repeat analysis using DNA pools. Individual genotyping of D10S558 and D10S1435 markers on chromosome 10 revealed statistically significant differences in the distribution of marker alleles in cases compared with controls ( Table 2 ). It is interesting that suggestive linkage of D10S1435 in early-onset nondiabetic ESRD was reported recently in black patients (30) . Also, a recent study reported linkage of a locus on chromosome 6q (D6S281) to essential hypertension in UK patients (31) . Relevant functional candidate genes are located within the vicinity of D10S558 and D10S1435, as well as for four other markers (D2S291, D4S2937, D6S281, and D17S515) that are worthy of further investigation ( Table 2) .
The discrepancies that were observed in allele frequency data that were obtained for DNA pooling and individual genotyping are not unexpected. However, this was minimized by careful construction and assessment of the pools and applying checks for false-positive outcomes that resulted from electrophoretic and/or PCR artifacts (e.g., stutter bands, length-dependent amplification). Recently, it was shown that multiple disjoined pools are preferable to single pools (32) , although there are additional cost considerations associated with this strategy.
The power of our study is limited by the sample size used, the confounding produced by our use of the pooling approach, and the low density of markers used. We recognize that genes that exert small effects or are not in linkage disequilibrium with the markers used cannot be identified by this method. Nevertheless, we have shown that this genome-wide microsatellite screen, using pools of DNA, is a cost-effective strategy for identifying positive associations between microsatellite markers and DN. Furthermore, we have demonstrated the utility of the GAMES method for the identification of possible functional candidate genes for this disease. We intend to assess haplotype tag SNP (33) within these candidate genes for association with DN using relatively large case-control studies such as the Juvenile Diabetes Research Foundation-funded Genetics of Kidneys in Diabetes (United Kingdom) case-control collection and Diabetes UK Warren 3 family collection; replication studies will be performed in case and control collections derived from other populations, such the US Genetics of Kidneys in Diabetes collection. 
